A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PALbociclib CoLlaborative Adjuvant Study. ANZ 1603 / ABCSG 42 / AFT-05 / BIG 14-03. PALLAS